All issues

List of references:

1. A. В. Гусев, А. А. Полежаев. Моделирование эволюции клеточной популяции при наличии максимально допустимой суммарной плотности клеток // Краткие сообщения по физике ФИАН. — 1997. — Т. 11–12. — С. 85–90. — zbMATH: Zbl 1186.20056.
2. Г. И. Соляник. Противоопухолевая антиангиогенная терапия: принципы, проблемы, перспективы // Онкология. — 2004. — Т. 8(2). — С. 206–208.
3. M. Benouchan, B. M. Colombo. Anti angiogenic strategies for cancer therapy // Int. J. Oncol. — 2005. — V. 27(2). — P. 563–571.
4. A. Dutour, M. Rigaud. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies // Anticancer Res. — 2005. — V. 25(6B). — P. 3799 — 3807.
5. S. D. Finley, A. S. Popel. Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions // J. Nat. Canc. Inst. — 2013. — V. 105(11). — P. 802–811. — DOI: 10.1093/jnci/djt093.
6. J. Folkman, P. Cole, . Tumor behavior in isolated perfused organs // Ann. Surg. — 1966. — V. 164. — P. 491. — DOI: 10.1097/00000658-196609000-00012.
7. J. Folkman. Tumor angiogenesis: therapeutic implications // N. Engl. J. Med. — 1971. — V. 285. — P. 1182–1186. — DOI: 10.1056/NEJM197108122850711.
8. G. Gasparini, R. Longo, M. Toi, N. Ferrara. Angiogenic inhibitors: a new therapeutic strategy in oncology // Nat. Clin. Pract. Oncol. — 2005. — V. 2(11). — P. 562–577. — DOI: 10.1038/ncponc0342.
9. Genentech. Avastin full Prescribing Information — Genentech(PDF). — 2011. — Gene.com.
10. A. Giese, R. Bjerkvig, M. E. Berens, M. Westphal. Cost of migration: invasion of malignant gliomas and implications for treatment // J. Clin. Oncol. — 2003. — V. 21. — P. 1624–1636. — DOI: 10.1200/JCO.2003.05.063.
11. D. Hanahan, R. A. Weinberg. The hallmarks of cancer // Cell. — 2000. — V. 100. — P. 57–70. — DOI: 10.1016/S0092-8674(00)81683-9.
12. A. H. Ko, A. P. Venook, E. K. Bergsland, R. K. Kelley, W. M. Korn, E. Dito, B. Schillinger, J. Scott, J. Hwang, M. A. Hwang. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer // Cancer Chemotherapy Pharmacology. — 2010. — V. 66(6). — P. 1051–1057. — DOI: 10.1007/s00280-010-1257-5.
13. A. V. Kolobov, V. V. Gubernov, A. A. Polezhaev. Autowaves in the model of infiltrative tumour growth with migration-proliferation dichotomy // Math. Model. Nat. Phenom. — 2011. — V. 6(7). — P. 27–38. — DOI: 10.1051/mmnp/20116703. — MathSciNet: MR2812637.
14. A. V. Kolobov, M. B. Kuznetsov. The study of angiogenesis effect on the growth rate of an invasive tumor using a mathematical model // Rus. J. Num. Anal. Math. Mod. — 2013. — V. 28(5). — P. 471–483. — MathSciNet: MR3296416. — zbMATH: Zbl 1276.92039.
15. J. Li, N. Zhou, K. Luo, W. Zhang, C. Wu, J. Bao. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy // Int. J. Mol. Sci. — 2014. — V. 15(9). — P. 15994–16011. — DOI: 10.3390/ijms150915994.
16. F. Milde, M. Bergdorf, P. Koumoutsakos. A Hybrid Model for Three-Dimensional Simulations of Sprouting Angiogenesis // Biophysical J. — 2008. — V. 95. — P. 3146 — 3160. — DOI: 10.1529/biophysj.107.124511. — MathSciNet: MR2283233. — ads: 2008BpJ....95.3146M.
17. O. N. Pyaskovskaya, D. L. Kolesnik, A. V. Kolobov, S. I. Vovyanko, G. I. Solyanyk. Analysis of Growth Kinetics and Proliferative Heterogeneity of Lewis Carcinoma Cells Growing as Unfed Culture // Experimental Oncology. — 2008. — V. 30. — P. 269–275.
18. M. Rocchetti, M. Germani, F. Del Bene, I. Poggesi, P. Magni, E. Pesenti, G. De Nicolao. Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an antiangiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts // Cancer Chemotherapy Pharmacology. — 2013. — V. 71(6). — P. 1147 — 1157. — DOI: 10.1007/s00280-013-2107-z.
19. M. Schneider, M. Tjwa, P. Carmeliet. A surrogate marker to monitor angiogenesis at last // Cancer Cell. — 2005. — V. 7(1). — P. 3–4. — DOI: 10.1016/j.ccr.2004.12.014.
20. K. R. Swanson, R. C. Rockne, J. Claridge, M. A. Chaplain, Jr. E. C. Alvord, A. R. A. Anderson. Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: In Silico Modeling Integrates Imaging and Histology // Cancer Res. — 2011. — V. 71. — P. 7366–7375. — DOI: 10.1158/0008-5472.CAN-11-1399.
21. B. Szomolay, T. D. Eubank, R. D. Roberts, C. B. Marsh, A. Friedman. Modeling the inhibition of breast cancer growth by GM-CSF // Journal of Theoretical Biology. — 2012. — V. 303. — P. 141–151. — DOI: 10.1016/j.jtbi.2012.03.024. — MathSciNet: MR2912960. — zbMATH: Zbl 1337.92118.
22. S. Takano, E. Ishikawa, K. Nakai, M. Matsuda, T. Masumoto, T. Yamamoto, A. Matsumura. Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trialr // OncoTargets and Therapy. — 2014. — V. 7. — P. 1551–1562. — DOI: 10.2147/OTT.S67621.
23. S. M. Weis, D. A. Cheresh. Tumor angiogenesis: molecular pathways and therapeutic targets // Nature Medicine. — 2011. — V. 17. — P. 1359 — 1370. — DOI: 10.1038/nm.2537.
24. M. Xiu, S. M. Turner, R. Busch, T. A. Gee, M. K. Hellerstein. Measurement of Endothelial Cell Proliferation Rate in vivo Using 2H2O Labeling: A Kinetics Biomaker of Angiogenesis // The FASEB Journal. — 2006. — V. 20. — Meeting Abstract Supplement A718.
25. G. M. Zhang, Y. M. Zhang, S. B. Fu, X. H. Liu, X. Fu, Y. Yu, Z. Y. Zhang. Effects of cloned tumstatinrelated and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells // Chin. Med. J. — 2008. — V. 121(22). — P. 2324–2330.